PMID- 23672402
OWN - NLM
STAT- MEDLINE
DCOM- 20130919
LR  - 20210102
IS  - 1365-3083 (Electronic)
IS  - 0300-9475 (Linking)
VI  - 78
IP  - 2
DP  - 2013 Aug
TI  - Current status and future perspectives of dendritic cell-based cancer 
      immunotherapy.
PG  - 167-71
LID - 10.1111/sji.12060 [doi]
AB  - Dendritic cells (DCs) are considered to be the most potent antigen-presenting 
      cells. Ever since the development of protocols for the in vitro generation of 
      DCs, their application in immunotherapy against various malignancies has been 
      explored. Even though the approach of using tumour antigen-presenting DCs in 
      therapeutic vaccination strategies has been shown to work effectively in mice and 
      look promising in in vitro studies, the actual clinical benefit for patients with 
      cancer has been marginal. There clearly is still room for improvement. In this 
      review, we will summarize recent clinical trials and findings and try to shed 
      some light on the current status and the future of DC-based cancer immunotherapy.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - H Yi, D
AU  - H Yi D
AD  - Broegelmann Research Laboratory, Department of Clinical Science, University of 
      Bergen, Bergen, Norway.
FAU - Appel, S
AU  - Appel S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - Antineoplastic Agents/therapeutic use
MH  - Cancer Vaccines/administration & dosage/genetics/*immunology
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Immunotherapy/*methods/trends
MH  - Mice
MH  - Neoplasms/immunology/pathology/*therapy
MH  - Treatment Failure
MH  - Vaccination
EDAT- 2013/05/16 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/04/29 00:00 [received]
PHST- 2013/05/03 00:00 [accepted]
PHST- 2013/05/16 06:00 [entrez]
PHST- 2013/05/16 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
AID - 10.1111/sji.12060 [doi]
PST - ppublish
SO  - Scand J Immunol. 2013 Aug;78(2):167-71. doi: 10.1111/sji.12060.